论文部分内容阅读
Fragment Based Drug Design(FBDD) has developed significantly over the past decade and is now widely accepted as a viable method of hit identification.A number of successful examples have been reported in the literature and FBDD has arguably had a contributory role in at least 18 drugs entering clinic.The size of fragments(molecular weight<250 Da) allows a smaller library of compounds to sample a large chemical space and provide higher hit rates than screening of larger compounds as in high throughput screening(HTS).Knowledge of the fragment binding mode is essential to the successful development of a screening hit.